Enterprise name	RIGAS FARMACEITISKA FABRIKA			
Registration No	0 0 0 3	8 0 0 0	7 6	
Registration No of tax-payer	4 0 0 0	3 0 0	0 7 6 5	
Address <u>Rīga , Duntes :</u>	16/22			
Phone7355550 , 73	255548	Fax	7391790	

The basic kind of activity: <u>manufacturing of medicines</u>

Unit: LVL and EUR

# BALANCE

for the period ended 31. December 2007

# a/s "Rīgas Farmaceitiskā Fabrika"

reg. No 40003000765 Rīga , Duntes iela 16/22

# **BALANCE SHEET**

# for the period ended 31 december 2007

Period

01.01.2007. 31.12.2007.

( LB currency EUR rate = 0.702804)

	( LB c	urrenc	/ EUR rate	t = 0.702804	4 <u>)</u>	
			The end of	The end of	The end of	
			reporting	reporting	reporting	The end
			period	period	period	reporting
ACCETO		Line	•			period
ASSETS		code	2007.g.	2007.g.	2006.g.	2006.g.
		couc	01.01	01.01	01.01	01.0131.
			31.12.	31.12.	31.12.	EUR
			LVL	EUR	LVL	EUR
1. Long - term investments						
I Intangible investments						
1 Research and development costs		10				
2 Concessions, patents, licenses, trade-marks and similar rights		20	14,470	20,589	19,782	28,1
3 Other intangible rights		21				
4 Intangible value of enterprise		30		-		
5 Advance payments of intangible investments		40				
TOTALLY	1		14470	20589	19782	28
II Fixed assets						
1 Lands, buildings, constructions and prennial plantations		60	379,307	539,705	293,146	417,1
2 Long-term leased fixed		70	120,220	104.010	112.540	161.6
3 Technological equipment and machines 4 Other fixed assets and inventory		80 90	129,329	184,019 145,117	113,548	161,5
•			101,989	145,117	79,488	113,1
5 Forming of fixed assets and costs of unfinished objects of constructio		100 110				
6 Advance payments for fixed assets  TOTALLY	2	110	610625	868841	486182	(01
III Long - term financial investments			010025	000041	480182	691
		120				
1 Participation in capital of related companies		130				
2 Loans to related companies		140				
3 Participation in capital of affiliated companies		150				
4 Loans to affiliated companies		160				
5 Other securities and investments		170				
6 Other loans		180				
7 Own stocks and shares		190				
8 Loans to joint owners and administration  TOTALLY		200		0		
1. TOTALLY			625095	889430	505964	719
			025095	009430	303904	/19
2. Current assets  I Stocks						
1 Row materials, direct materials and auxiliary materials	3	230	231,377	329,220	273,921	389,7
•	4	240	62,357	88,726	25,702	36,
2 Unfinished products	5					
3 Complete products and goods for sale	- 3	250	59,152	84,166	49,879	70,9
4 Unfinished orders 5 Advance payments for goods	6	260 270	14,407	20,499	16 677	66,
6 Work animals and productive animals	7	280	50	71	46,677 50.00	00,4
TOTALLY		280	367343	522682	396229	563
II Debtors			307343	322002	370227	300
Customers and client debts	8	300	249,246	354,645	151,829	216,0
2 Related companies debts		310		00 1,0 10	-	
3 Affiliated companies debts		320	_		_	
4 Other debts	9	330	286,489	407,637	76,124	108,3
5 Undeposited shares in business capital		340	,.07	101,007	,	200,
6 Short - term loans to joint owners and administration	9	350	152	216	180,000	256,
7 Accrued income	10	360	9,288	13,216	9,389	13,3
			545175	775714	417342	593
TOTALLY						
III Securities and participation in capitals						
		380				
III Securities and participation in capitals		380 390				
III Securities and participation in capitals  1 Participation in capital of related companies						
III Securities and participation in capitals  1 Participation in capital of related companies  2 Own stocks and shares		390	0	0	0	
III Securities and participation in capitals  1 Participation in capital of related companies  2 Own stocks and shares  3 Other securities and participation in capitals		390	0			
III Securities and participation in capitals  1 Participation in capital of related companies  2 Own stocks and shares  3 Other securities and participation in capitals  TOTALLY  IV Cash assets (TOTAL)  1 Cash assets	11	390	1,486	2,114	3,499	
III Securities and participation in capitals  1 Participation in capital of related companies  2 Own stocks and shares  3 Other securities and participation in capitals  TOTALLY  IV Cash assets (TOTAL)	11	390 400				4,5 1162 18825

LIABILITIES		Line code	The end of reporting period 2007.g. 01.01 31.12. LVL	The end of reporting period 2007.g. 01.01 31.12. EUR	The end of reporting period 2006.g. 01.01 31.12. LVL	The end of reporting period 2006.g. 01.0131.12 EUR
1. Equity capital						
Equity capital						
1 Stock or share capital (equity capital)	12	450	663,000	943,364	663,000	943,364
2 Stock issue extra charge		460	-		-	
Long - term investment re-estimation reserve     Prescribed reserves		470	-		-	
5 Reserves for own stocks and shares		480 490	-		-	
		500	-			
6 Reserves prescribed by enterprise 7 Other reserves		510	28,060	39,926	28,060	39,926
8 Retained profit of previous years		530	465,927	662,954	372,466	529,971
9 Retained profit of the year of accountant		540	206,065	293,204	93,461	132,983
TOTALLY		340	1363052	1939448	1156987	1646244
1. TOTALLY			1363052	1939448	1156987	1646244
2. Stockpiles			1000002	1505110	1100507	101021
Stockpiles						
1 Reserves for pensions and similar obligations		560				
2 Reserve for prospective taxes	13	570	29,150	41,477	27027.00	38,456
3 Other stockpiles	13	580	18,578	26,434	17,410	24,772
TOTALLY	10	200	47728	67911	44437	6322
2. TOTALLY			47728	67911	44437	6322
3. Creditors						
I Long - term debts						
1 Funded borrowings		600	_		_	
2 Borrowings for shares		610	_		_	
3 Bank borrowings		620	_		_	
4 Other borrowings		630	-		-	
5 Customers advanced payments		640	-		-	
6 Debts to suppliers and contractors		650	-		-	
7 Bills to be paid		660	_		-	
8 Borrowings from related companies		670	-		-	
9 Borrowings from affiliated companies		680	-		-	
10 Tax and social security payments		690	-		-	
11 Other creditors	14	700	-		6,669	9,489
12 Deferred income		710	-		-	
13 Dividends of the year of account		720	-		-	
14 Unpaid dividends of previous years		730	-		-	
TOTALLY			0	0	6669	948
II Short - term debts						
1 Funded borrowings		750	-		-	
2 Borrowings for shares		760	-		-	
3 Bank borrowings		770 780	-		-	
4 Other borrowings 5 Customers advanced payments	-	790	-		<u> </u>	
6 Debts to suppliers and contractors	14	800	91,573	130,297	86,700	123,363
7 Bills to be paid	14	810	91,373	130,297	- 50,700	123,303
8 Borrowings from related companies		820	-			
9 Borrowings from affiliated companies		830	_		_	
10 Tax and social security payments	14	840	22,751	32,372	17,020	24,217
11 Other creditors	14	850	13,995	19,913	11,221	15,966
12 Deferred income		860	-		-	
13 Dividends of the year of account		870	-		-	
14 Unpaid dividends of previous years		880	-		-	
TOTALLY			128319	182581	114941	16354
3. TOTALLY			128319	182581	121610	17303
BALANCE			1539099	2189941	1323034	1882508

# a/s "Rīgas Farmaceitiskā Fabrika "

reg. No 40003000765 Rīga , Duntes iela 16/22

# **PROFIT OR LOSS STATEMENT**

# for the period ended 31 december 2007

Period

01.01.2007.

31.12.2007.

(LB currency EUR rate = 0.702804)

		_ ( _	D carr	ency EUR rate	= 0.702004		
No	Special rate	Note	ROW	The end of reporting period 2007.g. 01.01 31.12. LVL	The end of reporting period 2007.g. 01.0131.12. EUR	The end of reporting period 2006.g. 01.0131.12. LVL	The end of reporting period 2006.g. 01.01 31.12. EUR
1.	Net turnover	15	10	2052164	2919966	1734747	2468323
2.	Cost of sales (prime cost)	16	20	-1188010	-1690386	-1095091	-1558174
3.	Gross profit or loss		30	864154	1229580	639656	910148
4.	Sales Distribution costs:	16	40	-245191	-348875	-212621	-302532
5.	Administration costs	16	50	-313530	-446113	-264024	-375672
6.	Other operating income	17	60	1843	2622	4506	6411
7.	Other operating expenses	18	70	-63511	-90368	-51762	-73651
8.	Income from participation in capital of related and affiliated companies		80				
9.	Income from securities and long - term loans		90				
10.	Other interests receivable and similar income		100				
11.	Amounts written off investments		110				
12.	Interest payable and similar changes		120				
13.	Profit or loss before extraordinary items and tax	19	130	243765	346846	115755	164705
14.	Extraordinary income		140				
15.	Extraordinary charges		150				
16.	Profit or loss before tax	19	160	243765	346846	115755	164705
17.	Tax on profit or loss for the financial period	20	170	-31399	-44677	-22587	-32138
18	Tax on profit (pustpone) or loss for the financial period	21	170	-2123	-3021	4445	6325
19	Other taxes	22	180	-4178	-5945	-4152	-5908
20	Profit or loss for the financial period	23	190	206065	293204	93461	132983
	EPS k-t			0.31	0.44	0.14	0.20

Enterprise name

# RĪGAS FARMACEITISKĀ FABRIKA A/S

Registration No 0 0 0 3 0 0 0 7 6

Registration No of tax-payer 4 0 0 0 3 0 0 0 7 6 5

Address Rīga , Duntes iela 16/22

Phone **7355550** Fax **7391790** 

Unit: LVL and EUR

## **OVERWIEW OF EQUITY CAPITAL CHANGES**

**Period** 01.01.2007.

			cy EUR rate =	0.702804)	31.12.2007.
	for the period ended 31 december 2007	The end of	The end of	The end of	The end of
		reporting period	reporting period	reporting period	reporting period
		2007.g. 01.01	2007.g. 01.01	2006.g. 01.01	2006.g. 01.01
		31.12. , LVL	31.12. , EUR	31.12. , LVL	31.12. , EUR
1.	Share capital				
	Post-balance residue on: 01.01.2007.	663,000	943,364	663,000	943,364
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2007.	663,000	943,364	663,000	943,364
2.	Share premium		0		
	Post-balance residue on: 01.01.2007.	0	0	0	_
	Increase :	0	0	0	
	Decrease :	0	0	0	
_	Post-balance residue on: 31.12.2007.	0	0	0	0
3.	Revaluation reserve of long-term investments				
	Post-balance residue on: 01.01.2007.	0	0	0	0
	Increase :	0	0	0	
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2007.	0	0	0	0
4.	Mandatory reserves				
	Post-balance residue on: 01.01.2007.	0	0	0	
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2007.	0	0	0	0
5.	Revaluation of own stocks of shares reserves				
	Post-balance residue on: 01.01.2007.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2007.	0	0	0	0
6.	Reserves determined by company statute				
	Post-balance residue on: 01.01.2007.	0	0	0	0
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2007.	0	0	0	0
7.	Other reserves				
	Post-balance residue on: 01.01.2007.	28,060	39,926	28,060	39,926
	Increase :	0	0	0	0
	Decrease :	0	0	0	0
	Post-balance residue on: 31.12.2007.	28,060	39,926	28,060	39,926
8.	Retained profit				
	Post-balance residue on: 01.01.2007.	465,927	662,954	372,466	529,971
	Post-balance residue on: 31.12.2007.	671,992	956,158	465,927	662,954
9.	Equity capital (total)				
	Post-balance residue on: 01.01.2007.	1,156,987	1,646,244	1,063,526	1,513,261
	Post-balance residue on: 31.12.2007.	1,363,052	1,939,448	1,156,987	1,646,244

# a/s "Rīgas Farmaceitiskā Fabrika "

reg. No 40003000765 Rīga , Duntes iela 16/22

## STATEMENT OF CASH FLOW

# for the period ended 31 december 2007

Period 01.01.2007.

		(LB current	cy EUR rate = 0	0.702804)	31.12.2007.
		The end of	The end of	The end of	The end of
	Note	reporting period	reporting period	reporting period	reporting period
	No	2007.g.	2007.g.	2006.g.	2006.g.
		01.0131.12. ,	01.0131.12. ,	01.0131.12. ,	01.0131.12. ,
		LVL	EUR	LVL	EUR
CASH FLOW from operating activit	ies				
Net profit (before enterprise income tax)		243765	346846	115755	164705
Corrections to adjust the profit of revision year to hard cash of economic activities:					
Depreciation of fixed assets and intangible investments		110838	157708	141076	200733
Profit or loss from sale of fixed assets and intangible investments		3173	4515	0	0
Expenditures per cent		0	0	0	0
Provisions fornon-used holidays		34517	49113	27832	39601
Other reserves		-33348	-47450	4445	6325
Debt expenditures of doubtful debtors		0	0	0	0020
Incoming of next periods		0	0	0	0
The taxes to deduct from net profit (property tax)		-4178	-5945	-4152	-5908
Paid enterprise income tax		-31399	-44677	-22587	-32138
The changes of the current assets and liabilities:					
Provisions		28885	41100	-57999	-82525
Debts of customers and subscribers		-97417	-138612	-86368	-122891
Expenditures of next periods		101	144	-763	-1086
Others debtors		-210365	-299322	-31484	-44798
Advance payments from customers		0	0	0	0
Debts to suppliers and contractors		4873	6934	10860	15452
Other creditors		8504	12100	-27762	-39502
Net cash provided by (used in) operating activities		57949	82454	68853	97969
CASH FLOW from investing activiti	ies				
Fixed assets purchase costs		-235659	-335313	-92265	-131281
Investment costs		0	0	0	0
Fixed assets selling income		2518	3583	0	0
Investment selling income		0	0	0	0
Company equity		0	0	0	0
Dividends received		0	0	0	0
Net cash provided by (used in) investing activities		-233141	-331730	-92265	-131281
CASH FLOW from financing activiti	ies	•			
Income from issue		0	0	0	0
Loans from credit institutions		0	0	0	0
Loans to creditirs		0	0	0	0
Payments for leasing liabilities		-6669	-9489	-9030	-12849
Other loans		179848	255901	30000	42686
Fixed assets investments		0	0	0	0
Cost of dividends		0	0	0	0
Net cash provided by (used in) financing activities		173179	246412	20970	29838
		•		_	
Net increase (decrease) in cash		-2013	-2864	-2442	-3475
Cash at the beginning of the year		3499	4979	5941	8453
Cash at the end of the year		1486	2114	3499	4979

# A/S "RĪGAS FARMACEITISKĀ FABRIKA"

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 December 2007

#### **ACCOUNTING POLICES**

## (1) Basis of preparation

The financial statements have been prepared in accordance with general accounting principles that correspond to the laws of the Republic of Latvia. All amounts presented in these financial statements are denominated in EUR of the Bank of Latvia LVL rate of exchange as at date of report (0,702804).

The financial statements reporting period is from 1 January 2007 till 31 December 2007.

The company's accounting polices have not changed in comparison with the previous year.

The financial statements reporting period is not verified by auditor.

## 1. INTANGIBLE ASSETS

	Expenditures on research activities LVL / EUR	Licenses and patents LVL / EUR	Company's intangible value LVL / EUR	Total LVL / <mark>EUR</mark>
Historical cost as of 1 January 2007	13 053 / 18 573	72 776 / 103 551	3 682 / 5 239	89 511 / 127 363
Additions	0	2 397 / 3 411	0	2 397 / 3 411
Disposals	0	(35 093)/ (49 933)	0	(35 093) / (49 933)
Historical cost as of 31 December 2007	13 053 / 18 573	40 080 / 57 029	3 682 / 5 239	56 815 / 80 841
Accumulated depreciation before 2007	13 053 / 18 573	52 994 / 75 404	3 682 / 5 239	69 729 / 99 216
Excluded on disposal		(34 693)/ (49 364)		(34 693) / (49 364)
Accumulated depreciation in 2007	0	7 309 / 10 400	0	7 309 / 10 400
Net book value as of 31 December 2007	0	14 470 / 20 589	0	14 470 / 20 589

#### 2. FIXED ASSETS

Z. FIXED ASSETS							
	Land LVL / EUR	Buildings LVL / EUR	Equipmen t LVL / EUR	Computin g equipment LVL / EUR	Other fixed assets LVL / EUR	Pendin g objects LVL / EUR	Total LVL / EUR
Historical cost as of 1	67 473 /	316 709 /	537 339 /	24 592 /	175 013 /	0	1 121 126 /
January 2007	96 005	450 636	764 563	34 991	249 021		1 595 216
Additions	0	108 726 /	64 907 /	4 555 /	55 074 /	0	233 262 /
		154 703	92 355	6 481	78 363		331 902
Disposals	0	0	(11 806)/	0	(12 268)/	0	(24 074)/
·			(16 798)		(17 456)		(34 254)
Historical cost as of	67 473 /	425 435 /	590 440 /	29 147 /	217 819 /	0	1 330 314 /
31 December 2007	96 005	605 339	840 120	41 472	309 928		1 892 864
Accumulated	0	91 036 /	423 791 /	16 407 /	103 710 /	0	634 944 /
depreciation before		129 532	603 000	23 344	147 566		903 442
2007							
Accumulated	0	22 565 /	46 229 /	5 041 /	28 914 /	0	102 749 /
depreciation in 2007		32 107	65 778	7 173	41 141		146 199
Excluded on disposal	0	0	(8 909)/	0	(9 095)/	0	(18 004)/
			(12 677)		(12 941)		(25 618)
Net book value as of	67 473 /	311 834 /	129 329 /	7 699 /	94 290 /	0	610 625 /
31 December 2007	96 005	443 700	184 019	10 955	134 162		868 841

#### 3. RAW AND ANCILLARY MATERIALS

Raw and ancillary materials are presented at their historical cost .

#### 4. GOODS FOR SALE

Goods for sale are presented in the financial statements at their net realizable value

#### 5. GOODS HELD ON CONSIGNMENT

Goods held on consignment are presented in the financial statements at their net realizable value

#### **6. ADVANCE PAYMENTS**

Amounts for raw and ancillary materials as well as advance payments for factory reconstruction designing works are presented in advance payments.

**7.** Work animals – guard dog.

#### 8. ACCOUNTS RECEIVABLE

All accounts receivable are short-term.

#### 9. OTHER DEBTORS

	As of 31 December 2007 LVL / EUR	As of 01 January 2007 LVL / <mark>EUR</mark>
Corporate income tax overpayment	0	0
Natural resources tax overpayment	0	0
VAT overpayment	143 489 / <del>204 166</del>	76 124 / <del>108 315</del>
VAT on unpaid invoices	0	0
Short-term loans to partners and employees	143 152 / 203 678	180 000 / <mark>256 117</mark>
Total	286 641 / 407 853	256 124 / <mark>364 432</mark>

VAT overpayment amount has been used to cover other taxes for 2008. Year.

Accounts receivable consist of loans to the Company's partner that will be settled in the end of year 2007.

#### **10. DEFERRED EXPENSES**

	As of 31	As of 01 January
	December 2007	2007
	LVL / EUR	LVL / EUR
Press subscription	516 / 734	959 / 1 364
Insurance	2627/3738	2 550 / 3 628
Other	6 145 / 8 744	5 880 / 8 367
Total	9 288 / 13 216	9 389 / 13 359

### **11. CASH**

	As of 31	As of 01
	December 2007	January 2007
	LVL / EUR	LVL / EUR
Cash on hand	772 / 1 098	901 / 1 282
Current account with NORDEA BANKA (LVL)	57/81	693 / <mark>986</mark>
Current account with HANSABANKA (LVL)	657 / <del>935</del>	1 905 / 2 711
Current account with HANSABANKA (currency)	0	0
Total	1 486 / 2 114	3 499 / 4 979

#### 12. SHARE CAPITAL

The share capital of the Company consisted of 663,000 LVL; that is 660,000 common voting shares and 3,000 common nonvoting shares with nominal value 1 LVL per share.

#### 13. PROVISIONS

Provisions for the reporting year consisted of vacation salaries and other remaining balance amounts.

#### 14. CREDITORS

THE GREEN GREEN	As of 31 December 2007 LVL / EUR	As of 01 January 2007 LVL / EUR
Lease (of cars)	0/0	6 669 / 9 489
Due to suppliers	91 573 / 130 297	86 700 / 123 363
Advance from suppliers	0	0
Salary for December	13 995 / 19 913	11 221 / 15 966
Taxes and social security payment	17 935 / 25 519	14 863 / 21 148
Corporate income tax	4816/6852	2 157 / 3 069

## 15. SALES

Total

LVL / EUR

128 319 / 182 581

121 610 / 173 035

Total sales	2 052 164 / 2 919 966
including : - operating income	2 035 231 / 2 895 873
- other operating expenses	16 933 / <mark>24 093</mark>

## **16. SALES EXPENSES**

Production expenses	1 188 010 / 1 690 386
Sales expenses	245 191 / 348 875
Administrative expenses	313 530 / 446 113
Total expenses	1 746 731 / 2 485 374

Profit for the year	305 433 / 434 592

## 17. OTHER OPERATING INCOME

Bank interest for application of funds from current account	50 / <mark>71</mark>
Income from currency fluctuations	1 578 / 2 245
Other	215 / 306
Total	1 843 / 2 622

## 18. OTHER OPERATING EXPENSES

Lease interest payment	249 / 354
Expenses from currency fluctuations	945 / 1 344
Fines paid	5/7
Provisions for vacations	22 398 / 31 870
Donations	7 200 / 10 245
Other	32 714 / 46 548
Total expenses	63 511 / 90 368

19. PROFIT FOR THE YEAR	243 765 / <mark>346 846</mark>
20. CORPORATE INCOME TAX	31 399 / 44 677
21. CORPORATE INCOME TAX /postpone/	2 123 / 3 021
(enlargement within current year)	
22. OTHER TAXES	4 178 / 5 945
23. NET PROFIT	206 065 / 293 204

<sup>24.</sup> The average number of employees in 2007 was 80.

## A/S "RĪGAS FARMACEITISKĀ FABRIKA"

## **GOVERNING BODY REPORT**

JSC "Riga Pharmaceutical Plant" is situated in Riga, 16/22 Duntes street and 6 Maza Ozolu street. The enterprise is the largest producer of finite pharmaceuticals, medical plants and drugs in Latvia. The factory was registered in Latvian Commercial Register of Enterprises in 2004. The Company has the licence for opening (activity) of drug manufacturing enterprise and has successfully passed the GMP certificate, as well as ISO 14001 standard.

The main business course of the enterprise is devoted to the manufacturing of medicines, medical goods and food supplements. All the 88 kinds of produced medicines are being realized in Latvia.

In 2007 the enterprise turnover was 2 919 966 EUR (2 052 164 LVL), which is about 18% more than in a corresponding period in 2006. The income of the enterprise in 2007 was 293 204 EUR (206 065 LVL), which is almost 2 times more than in a corresponding period of 2006. In the reporting period the prices for the production units have been increased.

We are planning to continue our work and to sell our production in all Baltic countries and also to accomplish the registration process for the first our medicines in Bulgaria.

The government of JSC "Riga Pharmaceutical Plant" (later in the text - Enterprise) is responsible for the preparing of intermediate finance report. Intermediate reports of the enterprise are not being audited. This management report based on accountant abstracts and incoming documents is considered to provide real and true information about the assets, liabilities and the whole financial position of the enterprise.

The government of the enterprise is responsible for using a corresponding register system, for preservation of assets of the enterprise and for investigation and elimination of the deceptions and delusions committed by the enterprise. The government of the enterprise is also responsible for the observance of Latvian legislation.